Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Geron Corporation

Market Cap 860M 755M 696M 651M 1.22B 81.43B 1.24B 8.36B 3.23B 39.95B 3.23B 3.16B 139B P/E 2026 *
-67x
P/E 2027 * 20.6x
Enterprise Value 839M 737M 679M 636M 1.19B 79.45B 1.21B 8.15B 3.16B 38.98B 3.15B 3.08B 135B EV / Sales 2026 *
3.59x
EV / Sales 2027 * 2.07x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+0.75%
1 week+14.41%
Current month+8.00%
1 month+5.47%
3 months-12.34%
6 months+1.50%
Current year+2.27%
1 week 1.17
Extreme 1.17
1.37
1 month 1.08
Extreme 1.08
1.37
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
20/05Free

Director

220,000 0.0343%
20/05Free

Director

220,000 0.0343%
20/05Free

Chairman

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%+14.41%-4.93%-57.28% 860M
+2.14%+6.81%+72.57%+123.91% 56.65B
-0.49%+6.98%+62.88%+67.95% 47.49B
+0.48%+1.25%-12.03%-15.42% 22.81B
+3.60%+6.94%-3.10%+411.77% 21.37B
+1.30%+0.71%+29.21%-17.51% 16.12B
+3.20%+7.18%+24.07%-34.39% 15.56B
-0.02%-1.46%+18.38%+158.51% 12.91B
0.00%+15.02%+133.24%+273.89% 12.86B
+1.43%-5.06%+23.53% - 11.67B
Average +1.19%+3.22%+34.38%+101.27% 21.83B
Weighted average by Cap. +1.20%+3.23%+45.00%+113.23%

Financials

2026 *2027 *
Net sales 234M 205M 189M 177M 332M 22.14B 337M 2.27B 879M 10.86B 877M 859M 37.76B 333M 293M 270M 252M 473M 31.56B 481M 3.24B 1.25B 15.48B 1.25B 1.22B 53.82B
Net income -13.95M -12.26M -11.3M -10.57M -19.81M -1.32B -20.14M -136M -52.5M -649M -52.38M -51.25M -2.25B 46.55M 40.89M 37.68M 35.27M 66.09M 4.41B 67.2M 452M 175M 2.16B 175M 171M 7.52B
Net Debt -20.97M -18.42M -16.97M -15.89M -29.77M -1.99B -30.27M -204M -78.9M -975M -78.72M -77.02M -3.39B -169M -148M -137M -128M -240M -16.01B -244M -1.64B -636M -7.85B -634M -621M -27.3B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
24/06/26 USD 1.350 +0.75% 13,076,775
22/06/26 USD 1.340 +6.35% 18,713,541
18/06/26 USD 1.260 +2.44% 22,995,891
17/06/26 USD 1.230 +4.24% 13,869,369
16/06/26 USD 1.180 +2.61% 10,258,721
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.340USD
Average target price
3.400USD
Spread / Average Target
+153.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!